Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| AXGN | Axogen, Inc. | 2025-10-16 15:10:04 | 16.74 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AXGN | 0000805928 | Axogen, Inc. | US05463X1063 | — | 411301878 | Nasdaq | 3845 | Electromedical & Electrotherapeutic Apparatus | 1231 | MN | 13631 PROGRESS BLVD. | ALACHUA | FL | 32615 | UNITED STATES | US | (386) 462-6817 | 13631 PROGRESS BLVD., ALACHUA, FL, 32615 | 13631 PROGRESS BLVD., ALACHUA, FL, 32615 | LECTEC CORP /MN/ | — | 2002-01-01 | — | — | — | 186,789,502 | 45,765,290 | 46,012,574 | Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator. | 2025-10-10 21:23:20 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 186,789,502 | -127,625,256 | -40.5914 | 44,343,785 | 1,137,539 | 2.6328 |
| 2023 | 314,414,758 | 92,893,029 | 41.934 | 43,206,246 | 604,328 | 1.4185 |
| 2022 | 221,521,729 | -420,385,493 | -65.4901 | 42,601,918 | 806,678 | 1.9301 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Marc Began | EVP | 2024 | 423,919 | — | 973,992 | 426,293 | 23,370 | 1,847,574 |
| Jens Kemp | Chief Marketing Officer | 2024 | 374,419 | — | 973,992 | 376,496 | 21,064 | 1,745,971 |
| Michael Dale | CEO, President | 2024 | 303,163 | — | 8,025,000 | 509,493 | 10,266 | 8,847,922 |
| Nir Naor | CFO | 2024 | 475,140 | — | 2,073,000 | 477,801 | 22,941 | 3,048,882 |
| Karen Zaderej | CEO, President | 2024 | 439,585 | — | 0 | 735,420 | 1,300,622 | 2,475,627 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 452 |
| 2023 | 428 |
| 2018 | 297 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 187,338,000 | 159,012,000 | 138,584,000 |
| Cost Of Revenue | 45,361,000 | 31,138,000 | 24,147,000 |
| Gross Profit | 141,977,000 | 127,874,000 | 114,437,000 |
| Research And Development Expenses | 27,767,000 | 28,333,000 | 27,158,000 |
| General And Administrative Expenses | 39,036,000 | 34,943,000 | 36,758,000 |
| Operating Expenses | 145,264,000 | 149,336,000 | 144,144,000 |
| Operating Income | -3,287,000 | -21,462,000 | -29,707,000 |
| Net Income | -9,964,000 | -21,716,000 | -28,948,000 |
| Earnings Per Share Basic | -0.23 | -0.51 | -0.69 |
| Earnings Per Share Diluted | -0.23 | -0.51 | -0.69 |
| Weighted Average Shares Outstanding Basic | 44,257,754 | 42,878,543 | 42,083,125 |
| Weighted Average Shares Outstanding Diluted | 44,257,754 | 42,878,543 | 42,083,125 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 27,554,000 | 31,024,000 | 15,284,000 |
| Marketable Securities Current | 5,928,000 | 0 | 33,505,000 |
| Accounts Receivable | 24,105,000 | 25,147,000 | 22,186,000 |
| Inventories | 33,183,000 | 23,020,000 | 18,905,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 99,217,000 | 88,004,000 | 98,075,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | — | — |
| Other Assets Non Current | 562,000 | 432,000 | 391,000 |
| Total Assets Non Current | 104,511,000 | 108,823,000 | 97,312,000 |
| Total Assets | 203,728,000 | 196,827,000 | 195,387,000 |
| Accounts Payable | 8,008,000 | 11,774,000 | 8,964,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 30,610,000 | 30,430,000 | 23,753,000 |
| Long Term Debt | 47,496,000 | 46,603,000 | 45,712,000 |
| Other Liabilities Non Current | 94,000 | — | — |
| Total Liabilities Non Current | 69,211,000 | 70,732,000 | 70,635,000 |
| Total Liabilities | 99,821,000 | 101,162,000 | 94,388,000 |
| Common Stock | 441,000 | 431,000 | 424,000 |
| Retained Earnings | -291,260,000 | -281,296,000 | -259,580,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 103,907,000 | 95,665,000 | 100,999,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 6,467,000 | 4,218,000 | 2,827,000 |
| Share Based Compensation Expense | 15,906,000 | 14,418,000 | 15,591,000 |
| Other Non Cash Income Expense | 0 | -56,000 | 0 |
| Change In Accounts Receivable | -392,000 | 2,691,000 | 4,639,000 |
| Change In Inventories | 10,163,000 | 6,054,000 | 3,656,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 125,000 | 6,509,000 | 660,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 4,535,000 | -5,716,000 | -16,066,000 |
| Purchases Of Marketable Securities | 5,773,000 | 10,203,000 | 39,247,000 |
| Sales Of Marketable Securities | 0 | 44,374,000 | 57,300,000 |
| Acquisition Of Property Plant And Equipment | 3,101,000 | 13,872,000 | 20,078,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -10,297,000 | 19,253,000 | -3,200,000 |
| Tax Withholding For Share Based Compensation | — | — | 0 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 2,300,000 | 1,964,000 | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | 0 | 0 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 2,290,000 | 1,954,000 | 1,794,000 |
| Change In Cash | -3,472,000 | 15,491,000 | -17,472,000 |
| Cash At End Of Period | 27,554,000 | 31,024,000 | 15,284,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 7,301,000 | 1,944,000 | 0 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.23 | -0.51 | -0.69 |
| Price To Earnings Ratio | -71.6522 | -13.3922 | -14.4638 |
| Earnings Growth Rate | -54.902 | -26.087 | 6.1538 |
| Price Earnings To Growth Ratio | 1.3051 | 0.5134 | -2.3504 |
| Book Value Per Share | 2.3478 | 2.2311 | 2.4 |
| Price To Book Ratio | 7.0194 | 3.0613 | 4.1584 |
| Ebitda | 4,709,000 | -14,663,000 | -25,497,000 |
| Enterprise Value | 749,309,785.92 | 308,439,448.69 | 450,417,587.5 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.4571 | 0.4871 | 0.4526 |
| Capital Expenditures | — | — | — |
| Free Cash Flow | — | — | — |
| Return On Equity | -0.0959 | -0.227 | -0.2866 |
| One Year Beta | 1.5311 | 1.7319 | 1.2659 |
| Three Year Beta | 1.3901 | 1.3995 | 1.2474 |
| Five Year Beta | 1.3025 | 1.276 | 1.2597 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Burke William P. Mr. | Director | 2025-10-06 | 736 | D | 1,557 |
| Burke William P. Mr. | Director | 2025-10-03 | 7,600 | D | 0 |
| Burke William P. Mr. | Director | 2025-10-03 | 14,571 | D | 2,293 |
| Burke William P. Mr. | Director | 2025-10-02 | 2,400 | D | 7,600 |
| Burke William P. Mr. | Director | 2025-10-02 | 7,620 | D | 16,864 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| RICE HALL JAMES & ASSOCIATES, LLC | 2025-09-30 | 2,027,195 | 113,632 | 17.84 |
| CWM, LLC | 2025-09-30 | 1,000 | 75 | 13.3333 |
| Future Financial Wealth Managment LLC | 2025-09-30 | 26,760 | 1,500 | 17.84 |
| Farther Finance Advisors, LLC | 2025-09-30 | 1,748 | 98 | 17.8367 |
| EXCHANGE TRADED CONCEPTS, LLC | 2025-09-30 | 1,046,138 | 58,640 | 17.84 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 188 | 2,460.92 | 0.001 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 16,200 | 212,058 | 0.0089 |
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 22,604 | 295,886.36 | 0.0225 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Total Market Index Fund | FZROX | 20,090 | 262,978.1 | 0.0009 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Extended Market Index Fund | FZIPX | 13,322 | 174,384.98 | 0.0095 |